HeartWorks has designed a first-of-its-kind platform that brings together physicians, scientists, and engineers to find and develop treatments for the most severe forms of congenital heart defects (CHD) to further advance research in genetics, stem cell biology, clinical trials, and cell-based manufacturing.
We get treatments out of the lab and into clinical trials to be conducted simultaneously in collaboration with a consortium of world-class medical institutions. Our vision is that our therapies will become a cure so children and adults born with CHD will no longer have to live with CHD.
Bioengineered Cardiac Tissue produces contracting heart muscle cells that are genetically identical to the patient’s own body; a “seed” that can be planted in a failing heart to help rebuild the weak muscle.
We are on a mission to create the world’s largest database of CHD patients. This will help us tailor clinical trials to the current CHD population and allow us to connect people with opportunities.